COMMUNIQUÉS West-GlobeNewswire

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
02/03/2026
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company, will continue to [...]
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
02/03/2026
CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Altimmune to Participate in Upcoming Investor Conferences
02/03/2026
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that [...]
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
02/03/2026
HEMANGEOL® is the only FDA-approved treatment for infantile hemangioma HEMANGEOL will be commercialized by Eton beginning May 1 st HEMANGEOL will be distributed through the company’s Eton Cares™ patient support program [...]
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
02/03/2026
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part B 16-week data [...]
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
02/03/2026
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt [...]
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
02/03/2026
JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision- [...]
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 [...]
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Supplemental Biologics License Application for Ziihera ® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with [...]
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
02/03/2026
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March 1. Most recently [...]
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
02/03/2026
ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today [...]
Novo Nordisk A/S - share repurchase programme
02/03/2026
Bagsværd, Denmark, 2 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Intuitive Expands Investment and Footprint in Europe
02/03/2026
Company begins direct operations in Italy, Spain, Portugal, Malta, San Marino, and associated territories SUNNYVALE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in [...]
Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
02/03/2026
Bagsværd, Denmark, 2 March 2026 – Novo Nordisk today announced an investment of 432 million euro (approx. DKK 3.2 billion) in its facility in Monksland, Athlone, Ireland. This tabletting facility will provide [...]
Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer
02/03/2026
PARIS, March 02, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in [...]
Notification of managers’ transactions
02/03/2026
ANNOUNCEMENT NO. 302 2 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Paul Chaplin Steps Down as CEO of Bavarian Nordic
02/03/2026
COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul [...]
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4
02/03/2026
Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 La désignation s’appuie sur les données positives d’une étude de phase 2 sur le rilzabrutinib dans la [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
02/03/2026
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing [...]

Pages